Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter.
about
Characterization and expression of a heart-selective alternatively spliced variant of alpha II-spectrin, cardi+, during development in the ratSuppression of extravillous trophoblast vascular endothelial growth factor expression and uterine spiral artery invasion by estrogen during early baboon pregnancyEstrogen regulation of placental angiogenesis and fetal ovarian development during primate pregnancy.Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis.Minireview: Estrogen receptor-beta: mechanistic insights from recent studies.Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus.Mechanistic and therapeutic implications of angiogenesis in endometriosis.HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland.Signal transducer and activator of transcription 3-stimulated hypoxia inducible factor-1alpha mediates estrogen receptor-alpha-induced mesenchymal stem cell vascular endothelial growth factor productionAromatase resistance mechanisms in model systems in vivo.Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozoleAromatase inhibitors and xenograft studies.Transcription factors Sp1 and Sp4 regulate TRPV1 gene expression in rat sensory neurons.Chromatin immunoprecipitation assay detects ERalpha recruitment to gene specific promoters in uterus.The association between hypoxia-inducible factor-1 α gene C1772T polymorphism and cancer risk: a meta-analysis of 37 case-control studies.Bevacizumab in metastatic breast cancer: when may it be used?SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancerTargeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines.The aryl hydrocarbon receptor is required for normal gonadotropin responsiveness in the mouse ovary.Genomics of estradiol-3-sulfate action in the ovine fetal hypothalamusThe organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cellsZoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interactionAntiangiogenic therapies in early-stage breast cancer.Effects of echinomycin on endothelin-2 expression and ovulation in immature rats primed with gonadotropins.Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence.The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor developmentMyocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor.Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.Regulation of placental villous angiopoietin-1 and -2 expression by estrogen during baboon pregnancyPlacental villous vascular endothelial growth factor expression and vascularization after estrogen suppression during the last two-thirds of baboon pregnancy.Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)Promotion of angiogenesis by human endometrial lymphocytes.HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2Regulation of expression of microvillus membrane proteins by estrogen in baboon fetal ovarian oocytes.Inhibition of oxygen-induced hypoxia-inducible factor-1alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro.Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.Sp1 and the 'hallmarks of cancer'.Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta.
P2860
Q28271818-7005CF34-822A-4774-845D-DEE51D77D2C4Q33345135-7570EC89-8139-4976-8E57-C103284B9E9BQ33580699-8BD52581-F925-4E3D-B9D2-667E5A35FA85Q33582902-24BF091C-F5C1-4A31-931B-2ABE5A694FA6Q33637261-CDB703FC-86F0-4064-8D1C-DB867B799B3CQ33770684-CE92C10D-D824-4EA8-B633-FC4CAB736725Q33779409-A5E488FB-92C6-491D-BA61-C576117C2237Q33940674-70B72D94-D48F-4FC4-9B07-00782DE48B7BQ34089612-32A7139F-B2F2-4F38-A9F8-9A6B17787D9AQ34589121-4B1BC833-995C-4303-BAB1-6C39A11861D2Q34789970-4BA9DBDC-F5D7-4167-80F6-09AA1F2822E3Q35043020-70BA0DFD-3F3E-4AFB-94B8-19FF3C9AC227Q35063692-394CC8BE-174E-408B-B7B3-D6470E935B6BQ35070097-1887EDFC-8214-4820-AD7A-C2523A9DDA57Q35075560-AAE5EBE0-0793-4C18-B544-270A9B15E79FQ35076351-D6B9780A-0CB7-4B57-94B6-97E8DFE3A47DQ35501899-34921833-924D-4374-8B56-3FE186DE747DQ35829696-84C7D4DB-3619-482D-B346-4F0A517D71DCQ36004566-05B0FC0B-EFA0-41E5-BF0C-BC7393FE072AQ36185468-305B1E26-12FF-4E81-B8B0-4DE1B975D1D8Q36229146-01123FD9-9DDB-4410-86DF-0479C4FB1708Q36295928-95CD6224-A1F1-4979-B0A6-DF69747E4067Q36318210-2FD92BE3-F55E-4B8D-ABB3-D958B0BB5B9FQ36374502-01457D85-102A-4976-9DFF-4C1ACB87A2FDQ36418331-550A19CD-DB35-48DC-80E5-A637F2DCAE28Q36642960-5B9D387E-C29B-4A95-B7E4-32904B76FEB5Q36758584-4DFE92F4-9DA8-45C9-9F69-AAAAE0C4FB34Q37101433-6159B20F-E721-49F9-A32D-DC2E837C1488Q37210431-A864365E-8716-426B-9C7A-B4DCCF122822Q37210436-4D930291-71E6-47CF-9999-BE2B4DB99C85Q37234829-4785B756-2789-49F7-A324-29D0CA5BB62CQ37248457-34970A34-0F99-434A-AE2A-EB82FA2BBBE3Q37381146-F3F29768-7259-4D42-8EA7-8BE09CB5349DQ37428401-087CBD1C-8BAB-4311-A29A-6D652B739C79Q37482931-8339C57B-7E4E-495D-B50B-596F32F06B9AQ37614573-19441FB7-084C-4617-A699-1D663769C91CQ37690655-14D4EA1A-18B2-497D-843B-139B60E489A9Q38267908-0D22EA02-5D80-446E-894B-2D69701F3380Q39048777-DCFBC11E-53AE-4F5B-B9F8-71C790CB0B0DQ39869920-7F92857D-1E3E-4701-88FF-5E61FB246CCA
P2860
Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Chromatin immunoprecipitation ...... helial growth factor promoter.
@en
type
label
Chromatin immunoprecipitation ...... helial growth factor promoter.
@en
prefLabel
Chromatin immunoprecipitation ...... helial growth factor promoter.
@en
P2093
P356
P1476
Chromatin immunoprecipitation ...... helial growth factor promoter.
@en
P2093
Armina A Kazi
Jenny M Jones
Robert D Koos
P304
P356
10.1210/ME.2004-0388
P577
2005-03-17T00:00:00Z